

## Chinese medtech startup Easy-Flow raises tens of millions of CNY in angel round

03 November 2022 | News

### Offering integrated package of peripheral interventional products

Shanghai Easy-Flow recently completed its Angel financing round by raising tens of millions of CNY (Chinese yuan renminbi), led by Legend Capital. The fresh capital will be used for the R&D of Easy-Flow's peripheral intervention pipeline.

Data shows that there are a large number of patients with peripheral vascular disease, of which about 40 million patients with lower extremity arteries and about 100 million patients with varicose veins. Given the number of patients is increasing yearly, there is a huge clinical demand foreseeable, indicating that the peripheral vascular interventional device trajectory is likely to be the next market worth CNY10 billion.

Founded in November 2021, Easy-Flow is developing products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases. It is expected that several products will be submitted for registration or initiated into clinical practice by 2030.

In addition to its independent R&D, Easy-Flow also simultaneously carries out external cooperation to further expand its product pipeline. Easy-Flow recently has reached a cooperation with Control Medical in the United States to introduce the FDA-approved Control(TM) mechanical thrombus removal system, which can be manually controlled by doctors to achieve efficient and controllable thrombus aspiration.